These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 3903679)

  • 1. Bioavailability study of two different 8-methoxypsoralen (8-MOP) preparations in patients receiving PUVA therapy.
    Nørgaard M; Hueg B; Staberg B
    Photodermatol; 1985 Aug; 2(4):252-6. PubMed ID: 3903679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Influence of retinoids on the bioavailability of methoxy-8-psoralen].
    Beani JC; Bonnot D; Berthod F; Boitard M; Reymond JL; Beriel H; Amblard P
    Ann Dermatol Venereol; 1991; 118(4):273-5. PubMed ID: 2069337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-Methoxypsoralen (Bergapten) for photochemotherapy. Bioavailability, phototoxicity, and clinical efficacy in psoriasis of a new drug preparation.
    Tanew A; Ortel B; Rappersberger K; Hönigsmann H
    J Am Acad Dermatol; 1988 Feb; 18(2 Pt 1):333-8. PubMed ID: 3279089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The pharmacokinetic and toxicologic profile of 8-methoxypsoralen. The basis for safe and effective PUVA therapy].
    Schmid J; Brickl R; Koss FW
    Derm Beruf Umwelt; 1988; 36(6):177-85. PubMed ID: 3069432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of psoralen and ultraviolet A on platelet functioning: an in vitro and in vivo study.
    Procaccini EM; Pandolfi G; Monfrecola G; Rotoli B
    Photodermatol Photoimmunol Photomed; 1992 Feb; 9(1):4-7. PubMed ID: 1390123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Difference in bioavailability between two brands of 8-methoxypsoralen and its impact on the clinical response in psoriatic patients.
    Herfst MJ; De Wolff FA
    Br J Clin Pharmacol; 1982 Apr; 13(4):519-22. PubMed ID: 7066167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacokinetic comparison of 3 8-methoxypsoralen preparations and clinical aspects].
    Walther T; Haustein UF; Quednow B; Meyer FP
    Hautarzt; 1990 Jun; 41(6):317-21. PubMed ID: 2380068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Standardizing 8-methoxypsoralen plasma profiles by using an emulsion form.
    Van Boven M; Roelandts R; Adriaens P; Daenens P; Degreef H; Kinget R
    J Am Acad Dermatol; 1985 May; 12(5 Pt 1):822-7. PubMed ID: 4008686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of 8-methoxypsoralen vs. 5-methoxypsoralen plus ultraviolet A therapy in patients with mycosis fungoides.
    Wackernagel A; Hofer A; Legat F; Kerl H; Wolf P
    Br J Dermatol; 2006 Mar; 154(3):519-23. PubMed ID: 16445785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic comparison of seven 8-methoxypsoralen brands.
    Menne T; Andersen KE; Larsen E; Solgaard P
    Acta Derm Venereol; 1981; 61(2):137-40. PubMed ID: 6165189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between 8-methoxypsoralen bath-water concentration and photosensitivity in bath-PUVA treatment.
    Tanew A; Kipfelsperger T; Seeber A; Radakovic-Fijan S; Hönigsmann H
    J Am Acad Dermatol; 2001 Apr; 44(4):638-42. PubMed ID: 11260539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of bioavailability and phototoxicity of two oral preparations of 5-methoxypsoralen.
    Stolk LM; Siddiqui AH; Westerhof W; Cormane RH
    Br J Dermatol; 1985 Apr; 112(4):469-73. PubMed ID: 3994922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioavailability of a new oral methoxsalen formulation. A serum concentration and photosensitivity response study.
    Sullivan TJ; Walter JL; Kouba RF; Maiwald DC
    Arch Dermatol; 1986 Jul; 122(7):768-71. PubMed ID: 3729509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic behaviour of sublingually administered 8-methoxypsoralen for PUVA therapy.
    Shephard SE; Langguth P; Panizzon RG
    Photodermatol Photoimmunol Photomed; 2001 Feb; 17(1):11-21. PubMed ID: 11169171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of psoriasis with psoralens and ultraviolet A. A double-blind comparison of 8-methoxypsoralen and 5-methoxypsoralen.
    Berg M; Ros AM
    Photodermatol Photoimmunol Photomed; 1994 Oct; 10(5):217-20. PubMed ID: 7880762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [8-methoxypsoralen serum content of problem patients in PUVA therapy].
    Walther T; Haustein UF
    Dermatol Monatsschr; 1990; 176(5-6):317-21. PubMed ID: 2227049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [8-Methoxypsoralen (8-MOP)-a new galenic form and its relation to 8-MOP serum levels (author's transl)].
    Nitsche V; Raff M; Bardach H
    Arch Dermatol Res; 1981; 271(1):11-7. PubMed ID: 7294879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bath-water PUVA therapy with 8-methoxypsoralen in mycosis fungoides.
    Weber F; Schmuth M; Sepp N; Fritsch P
    Acta Derm Venereol; 2005; 85(4):329-32. PubMed ID: 16191854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of time-dependent response to psoralen plus UVA (PUVA) treatment with topical 8-methoxypsoralen (8-MOP) gel in palmoplantar dermatoses.
    Engin B; Oguz O
    Int J Dermatol; 2005 Apr; 44(4):337-9. PubMed ID: 15811091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liquid formulations of 8-methoxypsoralen (8-MOP) and 5-MOP: a prospective double-blind crossover assessment of acute non-phototoxic adverse effects.
    George SA; Ferguson J
    Photodermatol Photoimmunol Photomed; 1992 Feb; 9(1):33-5. PubMed ID: 1390121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.